Menu

Foundation-led Drug Discovery

Virtual biotechs target and develop translational research.

Sep 1, 2008
Robert E. Pacifici and David P. Rankin

Foundations that support efforts to find treatments for rare diseases have stepped in to fill a significant funding gap caused by increasingly conservative venture capitalists and constraints at large pharmaceutical companies. Their considerable financial (in the tens of millions of dollars for many foundations) and intellectual involvement has triggered collaborative translational drug discovery efforts. CHDI Foundation, a virtual biotech exclusively focused on the discovery and development of drugs for Huntington's disease (HD) is one such organization.

Our enterprise is privately funded with a mandate to fast-track possible therapies for HD. Hence, CHDI strives to support all aspects of the drug development process from early exploratory efforts to identify and validate targets, to the screening, medicinal chemistry, preclinical optimization, on through the clinical and regulatory aspects of evaluating candidate molecules in human trials. Without wet-labs and staffed by more than forty individuals who bring a wealth of scientific, medical, business, legal and technical experience, CHDI's virtual model relies on the world-wide orchestration of over 400 full-time equivalent individuals working in academic institutions, contract research organizations, and biotechnology companies.

The challenge we face is to facilitate and expedite the sharing of research tools and results among academic and industrial HD investigators while protecting publication rights and the ownership of intellectual property. Our support to academic researchers is structured similarly to that provided to our corporate partners: through contracts. Investigators provide periodic progress reports that may be shared, in confidence, with other scientists; deliverables include access to any reagents and non-exclusive licenses to any intellectual property (such as assay system protocols) developed under a contract. To encourage research related to HD, all such reagents are quality controlled and made publicly accessible via a centralized repository (http://ccr.coriell.org/Sections/Collections/CHDI/?SsId=45).

University laboratories provide insights which allow us to identify and validate the targets, mechanisms, pathways, and networks that are the most relevant intervention points for HD. Once a target has been selected, we stress early proof-of-concept experiments since, unlike other drug discovery units, our singular focus on HD prevents us from opportunistically moving into alternate indications.

A network of fee-for-service contract research organizations (CROs) provides the brick-and-mortar laboratories and skilled staff to execute CHDI-sponsored drug development activities. In some cases, these efforts may be assembled from individual experiments (formulation, pharmacokinetic studies, blood-brain barrier penetration) at different places; but they also include semi-integrated programs in which iterative cycles of chemical synthesis and biological annotation drive structure-activity-relationships for projects at the lead optimization phase. Other programs, anti-sense against huntingtin for example, are conducted as joint ventures with biotech partners.

Preparation for clinical trials is proceeding along with efforts to develop therapeutics. These studies are an invaluable resource for developing biomarkers and rating scales and, in the near future, for therapeutic trials recruitment. CHDI has provided support for selected interventional trials which, to date, have only tested nutriceuticals or attempted to repurpose existing drugs. Our strong belief is that de novo development of NCEs (new chemical entities) will be necessary for a true disease-modifying therapy for HD. Our great hope is that once we have de-risked candidate HD therapies by demonstrating preliminary efficacy, that they will be attractive in-licensing opportunities for the large pharmaceutical companies who are much better poised to fund and conduct the later stage development activities.

Looking from the industrial and academic edges of the translational research chasm, any effort to build a bridge seemed daunting, but looking up from the basin, we saw an opportunity. Our solution: Provide a scaffold that can adapt to changes in the landscape and incorporate the combined knowledge and strengths of all the parties involved.

Robert E. Pacifici is Chief Scientific Officer and David P. Rankin is Chief Legal Officer of CHDI.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Enabling Genomics-Guided Precision Medicine

Enabling Genomics-Guided Precision Medicine

Download this eBook from Qiagen to learn more about the promise of precision medicine and how QCITM Interpret can help deliver better care with better knowledge.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!